This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción 71M
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Competidores de Myovant Sciences Ltd.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €25.19 |
| 52 Week High | €27.11 |
| 52 Week Low | €7.29 |
| Beta | 2.15 |
| 1 Month Change | 1.90% |
| 3 Month Change | 0.32% |
| 1 Year Change | 137.87% |
| 3 Year Change | 319.83% |
| 5 Year Change | 70.90% |
| Change since IPO | 129.67% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 71M | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | 0.9% | 0.8% | -0.5% |
| 1Y | 137.9% | -21.0% | 2.5% |
Rentabilidad vs. Industria: 71M exceeded the German Biotechs industry which returned 6.2% over the past year.
Rentabilidad vs. Mercado: 71M exceeded the German Market which returned -5.6% over the past year.
Volatilidad de los precios
| 71M volatility | |
|---|---|
| 71M Average Weekly Movement | 1.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 71M has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: 71M's weekly volatility has decreased from 11% to 2% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2016 | 579 | Dave Marek | myovant.com |
Resumen de fundamentos de Myovant Sciences Ltd.
| Estadísticas fundamentales de 71M | |
|---|---|
| Capitalización bursátil | €2.62b |
| Beneficios(TTM) | -€172.71m |
| Ingresos (TTM) | €356.29m |
6.9x
Ratio precio-ventas (PS)-14.2x
Ratio precio-beneficio (PE)¿Está 71M sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 71M | |
|---|---|
| Ingresos | US$379.11m |
| Coste de los ingresos | US$209.66m |
| Beneficio bruto | US$169.45m |
| Otros gastos | US$353.22m |
| Beneficios | -US$183.77m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.89 |
| Margen bruto | 44.70% |
| Margen de beneficio neto | -48.47% |
| Ratio deuda/patrimonio | -64.3% |
¿Cómo se ha desempeñado 71M a largo plazo?
Ver rendimiento histórico y comparativa